EMA Authorised: Winrevair (sotatercept) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised Winrevair (sotatercept) from Merck Sharp & Dohme B.V. for pulmonary hypertension and related hypertension therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• WINREVAIR (SOTATERCEPT-CSRK)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Merck Sharp & Dohme B.V.. Decision date: 24/03/2026. Orphan medicine